Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04916210 · ClinicalTrials.gov registry record
Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
A clinical trial of Mild Cognitive Impairment and Ischemic Stroke, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 8,000
- Enrollment target
- 20
- Study locations
NCT04916210 is a study of Mild Cognitive Impairment and Ischemic Stroke that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 8,000 participants, above the 1,232-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (549% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT04916210, a study of Mild Cognitive Impairment and Ischemic Stroke, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 8,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The overall goal of the DISCOVERY study is to better understand what factors contribute to changes in cognitive (i.e., thinking and memory) abilities in patients who experienced a stroke. The purpose of the study is to help doctors identify patients at risk for dementia (decline in memory, thinking and other mental abilities that significantly affects daily functioning) after their stroke so that future treatments may be developed to improve outcomes in stroke patients. For this study, a "stroke" is defined as either (1) an acute ischemic stroke (AIS, or blood clot in the brain), (2) an intracerebral hemorrhage (ICH, or bleeding in the brain), (3) or an aneurysmal subarachnoid hemorrhage (aSAH, or bleeding around the brain caused by an abnormal bulge in a blood vessel that bursts). The investigators hypothesize that: 1. The size, type and location of the stroke play an important role in recovery of thinking and memory abilities after stroke, and pre-existing indicators of brain health further determine the extent of this recovery. 2. Specific stroke events occurring in individuals with underlying genetic or biological risk factors can cause further declines in brain heath, leading to changes in thinking and memory abilities after stroke. 3. Studying thinking and memory alongside brain imaging and blood samples in patients who have had a stroke allows for earlier identification of declining brain health and development of individualized treatment plans to improve patient outcomes in the future.
Conditions Studied
Study Locations (20)
California
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Cedars Sinai Medical Center - Los Angeles
- University of California Los Angeles - Los Angeles
- University of California San Diego - San Diego
Florida
- Mayo Clinic - Jacksonville
- University of Miami Health System - Miami
Massachusetts
- Massachusetts General Hospital - Boston
- Boston Medical Center - Boston
Minnesota
- University of Minnesota Health - Minneapolis
- Mayo Clinic - Rochester
New York
- Icahn School of Medicine at Mount Sinai - New York
- Montefiore Medical Center - The Bronx
Arizona
- Barrow Neurological Institute - Phoenix
Colorado
- University of Colorado - Denver
Illinois
- The University of Chicago Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,000 participants |
| Start Date | 2021-03-05 |
| Est. Completion | 2026-08-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04916210
The ClinicalTrials.gov registry entry for NCT04916210 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 8,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,232-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (549% higher). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 0 interventions.
NCT04916210 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04916210 about?
NCT04916210 is a clinical study titled "Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY". The overall goal of the DISCOVERY study is to better understand what factors contribute to changes in cognitive (i.e., thinking and memory) abilities in patients who experienced a stroke. The purpose of the study is to help doctors identify patients at risk for dementia (decline in memory, thinking ...
What is the current status of trial NCT04916210?
This trial is currently recruiting. The enrollment target is 8,000 participants. The study started on 2021-03-05. Estimated completion is 2026-08-31.
What conditions does trial NCT04916210 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment, Ischemic Stroke, Intracerebral Hemorrhage, Subarachnoid Hemorrhage, Dementia, Vascular.
Who is sponsoring clinical trial NCT04916210?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04916210 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Wayfinding Intervention and Long-Term Memory
RECRUITING · NA
-
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
RECRUITING · Early Phase 1
-
MCI Speech in Noise
RECRUITING
-
Dual Task Perturbation Training for OAwMCI
RECRUITING · NA
-
Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease
RECRUITING
-
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.